News & Activities
Methodology Monday April Roundup
The latest #MethodologyMonday, the commentary by Young highlights the persistent underrepresentation of marginalised communities in clinical research, driven by structural barriers such as lack of trust, accessibility, and historical inequities. It underscores that while patient-centred strategies and industry-led efforts show promise, methodological limitations and inconsistent implementation hinder meaningful progress.
The article calls for stronger policy, funding incentives, and community-engaged approaches to ensure clinical trials better reflect the populations most affected by disease.
This #MethodologyMonday BMJ Medicine editorial by Collister and colleagues argues that despite widespread commitments to improving diversity in clinical trials, there remains a critical lack of robust evidence on which strategies actually work in practice. It highlights how underrepresentation continues to undermine the generalisability and external validity of research, calling for more rigorous evaluation and implementation of inclusive trial designs. Ultimately, the authors emphasise the need to move from aspirational goals to evidence-based, accountable actions that ensure clinical research reflects real-world populations.
Ref. Collister D, Song C, Ruzycki SM. Fostering diversity in clinical trials: need for evidence and implementation to improve representation. BMJ Medicine. 2024;3:e000984. https://doi.org/10.1136/bmjmed-2024-000984
This BMJ Open scoping review highlights the persistent underrepresentation of people with disabilities in clinical trials, raising concerns about both scientific validity and ethical integrity. It synthesizes global guidance into actionable domains—such as inclusive trial design, accessible recruitment, and supported consent—while emphasizing the importance of engaging disability communities throughout the research process. Despite growing awareness and emerging frameworks, the study stresses that implementation remains inconsistent and largely voluntary, calling for enforceable standards to drive truly inclusive clinical research.
